These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37435605)

  • 1. Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib.
    Ida H; Shimizu T; Nishino M; Nakamura Y; Yazaki S; Katsuya Y; Sato J; Koyama T; Iwasa S; Sudo K; Kondo S; Yonemori K; Shitara K; Shiono S; Matsuoka D; Yasuda K; Otake Y; Suzuki T; Takase T; Takashima S; Yamaguchi K; Semba T; Yamamoto N
    Cancer Res Commun; 2023 Jul; 3(7):1189-1199. PubMed ID: 37435605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort.
    Nishio M; Murakami S; Kawakami H; Okishio K; Tamiya M; Kobayashi H; Fujimoto D; Sugawara S; Kozuki T; Oya Y; Izumi H; Shiroyama T; Satouchi M; Yamamoto N; Kaname S; Matsuoka D; Otake Y; Takase T; Semba T; Azuma K
    Cancer Res Commun; 2024 Jan; 4(1):226-235. PubMed ID: 38181055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort.
    Kawazoe A; Yamamoto N; Sugimoto N; Kawakami H; Oshima T; Yamaguchi K; Hino K; Hirao M; Kurokawa Y; Kawakami T; Tsuda M; Hara H; Kaname S; Matsuoka D; Otake Y; Yasuda K; Takase T; Takashima S; Semba T; Muro K
    Clin Cancer Res; 2024 Apr; 30(7):1264-1272. PubMed ID: 38295160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors.
    Sato J; Shimizu T; Koyama T; Iwasa S; Shimomura A; Kondo S; Kitano S; Yonemori K; Fujiwara Y; Tamura K; Suzuki T; Takase T; Nagai R; Yamaguchi K; Semba T; Zhao ZM; Ren M; Yamamoto N
    Clin Cancer Res; 2022 May; 28(9):1783-1791. PubMed ID: 35180771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort.
    Shitara K; Hirao M; Iwasa S; Oshima T; Komatsu Y; Kawazoe A; Sato Y; Hamakawa T; Yonemori K; Machida N; Yuki S; Suzuki T; Okumura S; Takase T; Semba T; Zimmermann B; Teng A; Yamaguchi K
    Clin Cancer Res; 2023 Apr; 29(8):1460-1467. PubMed ID: 36730323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the breast cancer expansion cohort.
    Masuda N; Ono M; Mukohara T; Yasojima H; Shimoi T; Kobayashi K; Harano K; Mizutani M; Tanioka M; Takahashi S; Kogawa T; Suzuki T; Okumura S; Takase T; Nagai R; Semba T; Zhao ZM; Ren M; Yonemori K
    Eur J Cancer; 2022 Jun; 168():108-118. PubMed ID: 35500404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314).
    Schafer ES; Rau RE; Berg S; Liu X; Minard CG; D'Adamo D; Scott R; Reyderman L; Martinez G; Devarajan S; Reid JM; Fox E; Weigel BJ; Blaney SM
    Pediatr Blood Cancer; 2018 Aug; 65(8):e27066. PubMed ID: 29719113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours.
    Evans TRJ; Dean E; Molife LR; Lopez J; Ranson M; El-Khouly F; Zubairi I; Savulsky C; Reyderman L; Jia Y; Sweeting L; Greystoke A; Barriuso J; Kristeleit R
    Br J Cancer; 2019 Feb; 120(4):379-386. PubMed ID: 30679780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial.
    Morgan RJ; Synold TW; Longmate JA; Quinn DI; Gandara D; Lenz HJ; Ruel C; Xi B; Lewis MD; Colevas AD; Doroshow J; Newman EM
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):897-907. PubMed ID: 26362045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposomal eribulin for advanced adenoid cystic carcinoma, gastric cancer, esophageal cancer, and small cell lung cancer.
    Udagawa H; Takahashi S; Hirao M; Tahara M; Iwasa S; Sato Y; Hamakawa T; Shitara K; Horinouchi H; Chin K; Masuda N; Suzuki T; Okumura S; Takase T; Nagai R; Yonemori K
    Cancer Med; 2023 Jan; 12(2):1269-1278. PubMed ID: 35864593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.
    Goel S; Mita AC; Mita M; Rowinsky EK; Chu QS; Wong N; Desjardins C; Fang F; Jansen M; Shuster DE; Mani S; Takimoto CH
    Clin Cancer Res; 2009 Jun; 15(12):4207-12. PubMed ID: 19509177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors.
    Tan AR; Rubin EH; Walton DC; Shuster DE; Wong YN; Fang F; Ashworth S; Rosen LS
    Clin Cancer Res; 2009 Jun; 15(12):4213-9. PubMed ID: 19509146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial.
    Heinhuis KM; Carlino M; Joerger M; Di Nicola M; Meniawy T; Rottey S; Moreno V; Gazzah A; Delord JP; Paz-Ares L; Britschgi C; Schilder RJ; O'Byrne K; Curigliano G; Romano E; Patah P; Wang R; Liu Y; Bajaj G; Siu LL
    JAMA Oncol; 2020 Jan; 6(1):100-107. PubMed ID: 31697308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors.
    Juric D; Barve M; Vaishampayan U; Roda D; Calvo A; Jañez NM; Trigo J; Greystoke A; Harvey RD; Olszanski AJ; Opyrchal M; Spira A; Thistlethwaite F; Jiménez B; Sappal JH; Kannan K; Riley J; Li C; Li C; Gregory RC; Miao H; Wang S
    Cancer Med; 2024 Mar; 13(5):. PubMed ID: 38501219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eribulin mesylate in patients with refractory cancers: a Phase I study.
    Mukohara T; Nagai S; Mukai H; Namiki M; Minami H
    Invest New Drugs; 2012 Oct; 30(5):1926-33. PubMed ID: 21887501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
    Pernas S; Martin M; Kaufman PA; Gil-Martin M; Gomez Pardo P; Lopez-Tarruella S; Manso L; Ciruelos E; Perez-Fidalgo JA; Hernando C; Ademuyiwa FO; Weilbaecher K; Mayer I; Pluard TJ; Martinez Garcia M; Vahdat L; Perez-Garcia J; Wach A; Barker D; Fung S; Romagnoli B; Cortes J
    Lancet Oncol; 2018 Jun; 19(6):812-824. PubMed ID: 29706375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second-line chemoimmunotherapy with nivolumab and paclitaxel in immune-related biomarker-enriched advanced gastric cancer: a multicenter phase Ib/II study.
    Lee CK; Lee JB; Park SJ; Che J; Kwon WS; Kim HS; Jung M; Lee S; Park SR; Koo DH; Lee HW; Bae WK; Jeung HC; Hwang IG; Kim H; Nam CM; Chung HC; Rha SY
    Gastric Cancer; 2024 Jan; 27(1):118-130. PubMed ID: 37906316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the pharmacokinetics of a liposomal formulation of eribulin mesylate (E7389) in mice.
    Yu Y; Desjardins C; Saxton P; Lai G; Schuck E; Wong YN
    Int J Pharm; 2013 Feb; 443(1-2):9-16. PubMed ID: 23313921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma.
    Chen TW; Hsu CL; Hong RL; Lee JC; Chang K; Yu CW; Chen SC; Guo JC; Chen ML; Hsu MC; Kung TF; Cheng AL; Yen CC
    Clin Cancer Res; 2022 Dec; 28(23):5058-5065. PubMed ID: 36129471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TAS-116 (Pimitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704).
    Kawazoe A; Itahashi K; Yamamoto N; Kotani D; Kuboki Y; Taniguchi H; Harano K; Naito Y; Suzuki M; Fukutani M; Higuchi T; Ikeno T; Wakabayashi M; Sato A; Koyama S; Nishikawa H; Shitara K
    Clin Cancer Res; 2021 Dec; 27(24):6709-6715. PubMed ID: 34593531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.